Back HBV Disease Progression

HBV Disease Progression

AASLD 2011: Upping Entecavir Dose Does Not Improve Hepatitis B Treatment Response

Doubling the usual dose of entecavir (Baraclude) did not increase its effectiveness for treating chronic hepatitis B, according to a study presented at the 62nd Annual Meeting of the American Association for the Study of Liver Disease (AASLD 2011) this month in San Francisco.alt

Read more:

AASLD 2011: Good Response to Entecavir Reduces Risk of Hepatitis B Liver Disease Progression

Chronic hepatitis B patients who achieve HBV DNA viral load suppression on entecavir (Baraclude) have a lower risk of liver failure, hepatocellular carcinoma, and death than non-responders, according to study findings presented this month at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) in San Francisco.alt

Read more:

Changes Proposed for Allocation of Donated Livers

For some patients transplantation is the only treatment for advanced liver disease due to chronic hepatitis B, hepatitis C, liver cancer, alcoholism, or other causes. But the supply of donor livers does not meet the demand, meaning that many people die while on a waiting list. As described in the September 2011 issue of Liver Transplantation, experts have been meeting for the past 2 years to develop a modified allocation system that aims to reduce wait-list mortality.

Read more:

AASLD 2011: Engineered Poxvirus Shows Promise for Treating Advanced Liver Cancer

A genetically engineered vaccinia poxvirus (JX-594) can rapidly destroy tumors and prolong survival of people with advanced hepatocellular carcinoma (HCC), according to a late-breaker presentation at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2011) this week in San Francisco.alt

Read more:

Hepatitis Delta Found in 15% of HIV/HBV Coinfected People, Increases Risk of Death

Approximately 15% of people with HIV who test positive for hepatitis B surface antigen (HBsAg) also carry hepatitis delta virus (HDV), a defective virus that can only replicate in the presence of hepatitis B virus (HBV) but can lead to more severe liver damage, according to a recent European study.

Read more: